Institution of Neurobiology, Caring Sciences, and Society, Karolinska Institute, Stockholm, Sweden.
Neuropsychiatr Dis Treat. 2010 Apr 7;6:93-7. doi: 10.2147/ndt.s9138.
Patients with Parkinson's disease (PD) or Parkinsonian syndromes often report excessive daytime sleepiness (EDS). The aim of this study was to evaluate the effects of the psychostimulant modafinil on elderly, institutionalized, severely impaired PD patients with EDS.
A three-week open study on ten institutionalized PD patients scoring >10 points on the Epworth Sleepiness Scale (ESS) with modafinil eventually on 100 mg twice a day. Patients were assessed at the start, week 1, and week 3 with ESS, Clinical Global Impression (CGI) scale severity of PD and appetite.
Reduction of ESS score and PD severity over time were found as well as a significant increase in appetite and reduction in CGI score.
Modafinil 100 mg twice a day was safe and modestly effective for the treatment of EDS in elderly, institutionalized PD patients. Sustaining wakefulness throughout all stages of PD is crucial for participating in life, maintaining social life, and improving quality of life.
帕金森病（PD）或帕金森综合征患者常报告白天过度嗜睡（EDS）。本研究旨在评估促智药莫达非尼对伴有 EDS 的老年、住院、严重受损的 PD 患者的影响。
对 10 名住院 PD 患者进行为期 3 周的开放性研究，这些患者的 Epworth 嗜睡量表（ESS）评分>10 分，最终接受莫达非尼 100mg，每日两次。患者在开始时、第 1 周和第 3 周进行 ESS、临床总体印象（CGI）量表 PD 严重程度和食欲评估。
发现 ESS 评分和 PD 严重程度随时间降低，同时食欲显著增加，CGI 评分降低。
莫达非尼 100mg，每日两次，用于治疗老年住院 PD 患者的 EDS 是安全且适度有效的。在 PD 的所有阶段保持清醒对于参与生活、维持社交生活和提高生活质量至关重要。
